ArticlePloS one2021

Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.

Simone Rivolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.